PMID- 29754328
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20190111
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 38
IP  - 8
DP  - 2018 Aug
TI  - HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with 
      polyangiitis: a retrospective pilot study.
PG  - 1531-1538
LID - 10.1007/s00296-018-4043-z [doi]
AB  - We examined whether resolved hepatitis B virus (HBV) infection was associated 
      with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), and 
      affected AAV activity at diagnosis and prognosis during the follow-up. We 
      reviewed the electronic medical records of 153 AAV patients, and included 91 
      hepatitis B surface antigen (HBsAg)-negative patients having results of both 
      antibody to hepatitis B core antigen (anti-HBc) and surface antigen (anti-HBs). 
      We collected clinical and laboratory data, Birmingham vasculitis activity score 
      (BVAS) and five factor scores (FFS) at diagnosis and relapse rates during the 
      follow-up. We divided patients into the two groups according to the presence of 
      anti-HBc and compared variables between them in patients with AAV or those with 
      each variant. The mean age and follow-up duration were 59.8 +/- 15.2-year-old and 
      48.0 +/- 47.5 months. Fifty patients (54.9%) had anti-HBc, and 61 patients (67.0%) 
      had anti-HBs. Only thirty-six (39.6%) patients had ever experienced relapse after 
      remission. There were no remarkable differences between HBsAg-negative AAV 
      patients with and without anti-HBc. However, in eosinophilic granulomatosis with 
      polyangiitis (EGPA) patients, patients with HBs-negative/anti-HBc-positive 
      (resolved HBV infection) showed the higher initial mean BVAS and FFS (2009) than 
      those without. Patients having anti-HBc exhibited significantly increased risk of 
      relapse of EGPA than those having not (RR 16.0). Also, EGPA patients with 
      HBs-negative/anti-HBc-positive showed meaningfully lower cumulative relapse-free 
      survival rates than those without during the follow-up duration (p = 0.043). In 
      conclusion, resolved HBV infection may importantly influence vasculitis activity 
      at diagnosis and subsequently relapse after remission in EGPA patients.
FAU - Lee, Sang-Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, South Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Kim, Do Young
AU  - Kim DY
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
AD  - Yonsei Liver Center, Severance Hospital, Seoul, South Korea.
FAU - Ahn, Sang Hoon
AU  - Ahn SH
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
AD  - Yonsei Liver Center, Severance Hospital, Seoul, South Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, South Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Han, Kwang-Hyub
AU  - Han KH
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
AD  - Yonsei Liver Center, Severance Hospital, Seoul, South Korea.
FAU - Park, Jun Yong
AU  - Park JY
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. 
      DRPJY@yuhs.ac.
AD  - Yonsei Liver Center, Severance Hospital, Seoul, South Korea. DRPJY@yuhs.ac.
LA  - eng
GR  - HI14C1324/A grant from the Korea Health Technology R&D Project through the Korea 
      Health Industry Development Institute, funded by the Ministry of Health and 
      Welfare, Republic of Korea/
GR  - 2017R1D1A1B03029050/Basic Science Research Program through the National Research 
      Foundation of Korea (NRF) funded by the Ministry of Education/
PT  - Journal Article
DEP - 20180512
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (TAB3 protein, human)
SB  - IM
CIN - Rheumatol Int. 2018 Aug;38(8):1585-1586. PMID: 29948001
MH  - Adaptor Proteins, Signal Transducing
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*immunology
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Female
MH  - Granulomatosis with Polyangiitis/blood/*immunology
MH  - Hepatitis B
MH  - Hepatitis B Surface Antigens/*blood
MH  - Hepatitis B virus
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Remission Induction
MH  - Retrospective Studies
OTO - NOTNLM
OT  - ANCA-associated vasculitis
OT  - Activity
OT  - Eosinophilic granulomatosis with polyangiitis
OT  - Relapse
OT  - Resolved HBV infection
EDAT- 2018/05/14 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/05/14 06:00
PHST- 2018/03/04 00:00 [received]
PHST- 2018/05/05 00:00 [accepted]
PHST- 2018/05/14 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/05/14 06:00 [entrez]
AID - 10.1007/s00296-018-4043-z [pii]
AID - 10.1007/s00296-018-4043-z [doi]
PST - ppublish
SO  - Rheumatol Int. 2018 Aug;38(8):1531-1538. doi: 10.1007/s00296-018-4043-z. Epub 
      2018 May 12.